Lanreotide

• Catalog No.: Lanreotide
• CAS Number: 108736-35-2
• M. F.: C54H69N11O10S2
• M. W.: 1096.32336

SYNONYMS

• IUPAC name: 2-({19-[2-amino-3-(naphthalen-2-yl)propanamido]-10-(4-aminobutyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-(propan-2-yl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}formamido)-3-hydroxybutanamide
• IUPAC Traditional name: 2-({19-[2-amino-3-(naphthalen-2-yl)propanamido]-10-(4-aminobutyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-7-isopropyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}formamido)-3-hydroxybutanamide
• Brand Name: Somatuline

DATABASE IDS

• PubChem CID: 71349
• ATC CODE: H01CB03
• CHEMBL: 1201185
• CAS Number: 108736-35-2
• IUPHAR ligand ID: 2031
• Chemspider ID: 64450
• Unique Ingredient Identifier: 0G3DE8943Y
• Wikipedia Title: Lanreotide

PROPERTIES

• Admin Routes: Intramuscular, subcutaneous
• Bioavailability: Approximately 80%
• Excretion: Mostly biliary
• Half Life: 2 hours (immediate release); 5 days (sustained release)
• Legal Status: POM (UK)
• Legal Status: Rx-only (US)
• US Licence: Lanreotide
• Metabolism: In GI tract
• Pregnancy Category: C (US)
• Pregnancy Category: C (Australia)
• Protein Bound: 78%